Trials / Conditions / Estrogen Receptor Positive Tumor

Estrogen Receptor Positive Tumor

18 registered clinical trials studyying Estrogen Receptor Positive Tumor — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Ph 2 Elacestrant in ER Positive Uterine Sarcomas NCT07467772	Dana-Farber Cancer Institute	Phase 2
Recruiting	Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients NCT06474988	European Institute of Oncology	—
Recruiting	PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226	QuantumLeap Healthcare Collaborative	Phase 1
Recruiting	OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328	Gangnam Severance Hospital	Phase 4
Unknown	Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Canc NCT04997798	First Affiliated Hospital of Zhejiang University	Phase 2
Withdrawn	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117	QuantumLeap Healthcare Collaborative	Phase 1
Recruiting	The MASTER Study (MAmmary Cancer STatin ER Positive Study) NCT04601116	Aarhus University Hospital	Phase 3
Completed	To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer NCT03644186	ETOP IBCSG Partners Foundation	Phase 2
Completed	Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression NCT03870399	AC Camargo Cancer Center	Phase 2
Active Not Recruiting	A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Recep NCT04086875	Thomas Jefferson University	N/A
Unknown	Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer NCT03750396	Gangnam Severance Hospital	Phase 2
Active Not Recruiting	Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer NCT03503799	North Eastern German Society of Gynaecological Oncology	—
Completed	Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Brea NCT03250676	Eisai Inc.	Phase 1 / Phase 2
Completed	Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractan NCT02997995	UNICANCER	Phase 2
Active Not Recruiting	Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases NCT02603679	Thomas Hatschek	Phase 2
Terminated	A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer NCT01548534	University Hospital, Tours	Phase 3
Completed	Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Bre NCT01439282	Eisai Inc.	Phase 2
Unknown	Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women NCT01266213	Samsung Medical Center	Phase 2